Navigation Links
Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
Date:12/8/2008

to convene the special meeting.

Following these refusals, the investor group initiated a campaign for conversion of company ADRs into ordinary shares to bring about the special meeting. This campaign is continuing.

Commenting on the group's ongoing campaign for conversion of Trinity Biotech ADRs to company ordinary shares, Tom Reidy stated that, "The current Board decision forcing shareholders to convert their ADRs to bring about a special meeting of shareholders has been met with considerable outrage and a wide-spread call to action. Despite the cost and inconvenience involved in this process, we are pleased with the number of shareholders who are stepping forward to take this important action to impose accountability on company management. Like us, they have come to the conclusion that a board controlled by independent directors is essential to an increase in company share value. We anticipate reporting very soon that our collective efforts will have brought about an opportunity to finally vote and be heard."

Speaking on Mr. Winter's qualifications to serve on the Trinity Biotech board, Mr. Reidy stated, "Robert's understanding of the medical device markets, especially of an international nature, brings important transactional expertise to the team. His background in capital formation and investment strategy, together with his extensive record in devising new and unique partnership opportunities, make Robert an important addition to our independent team."

Tom Reidy, 816-260-8476, tjreidy3@hotmail.com


'/>"/>
SOURCE KC Investor Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. DuPont Leaders Brief Investors on Agriculture Businesses
3. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
4. Thermo Fisher Scientific to Present at Investor Conferences
5. Modigene to Present at the Roth 2007 New York Investor Conference
6. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
9. Suntech to Attend Upcoming Investor Conferences and Industry Events
10. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
11. American Oriental Bioengineering Announces Participation in September Investor Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...n American countries have an opportunity to take t...chers from the University of Valencia (UV), workin...ed the productive fabric of the Spanish biotechnol...d and plant sectors have more clout than those in ...pplied to food and plants has been overlooked by t...
(Date:11/20/2009)...EATTLE, Nov. 20 Cell The...nced today that the Ninth Circuit Court of Appeals...at CTI should be allowed to pursue all of its clai...o the District Court for trial. CTI filed a compl...rty reimbursement consultant for CTI,s product TRI...
(Date:11/19/2009)...LE, Nov. 19 Omeros Corpo...financial results for the third quarter ended Sept...er 30, 2009, Omeros reported a net loss of $3.9 mi...ss of $7.4 million, or $2.54 per share, for the sa...mber 30, 2009, the Company reported a net loss of ...
(Date:11/19/2009)...ALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswir...on Resources find that the leading driver of antib...is broad-spectrum activity against gram-positive a...organisms that can cause nosocomial pneumonia, sur...imarily for agents that provide appropriate covera...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...th Systems, Inc. (Nasdaq: DCTH ), a medical tec...us Hepatic Perfusion ("PHP") System for the treatm...the first fifty percent (46 of 92) of patients hav...eating metastatic cutaneous and ocular melanoma to...rs in this trial continue to evaluate and enroll p...
...1 , - SCRIP Awards Recognises the Best and Brig...stries Worldwide, - Glenmark is the Only Indian...ecognition, , The best and brightest of the ...ted at a glittering ceremony in London at the 2008... Peter Sissons on December 10th. At this award,cer...
...iate Action to Protect and Maximize Shareholder Va... Fund, L.P., the owner, together with its affiliat...mon stock of Avigen, Inc. (Nasdaq: AVGN ) announ...,s Board of Directors expressing its displeasure w...ruction of shareholder value. , , The text ...
Other Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5
(Date:11/19/2009)...an 2: The offspring of two inbred strains tend to ...ng the gene-level variability that leads to this p...ld boost our ability to custom-tailor crops for sp...man consumption or high glucose content for biomas... sequence of the common corn strain B73, Universit...
(Date:11/19/2009)...t Louisiana Tech University has found that a natur...bicide against giant salvinia. , Giant salvinia ...ock all sunlight penetration into bodies of water,...ns, it,s been reported that giant salvinia can dou...er, professor of biological sciences at Louisiana ...
(Date:11/19/2009)...s identified thousands of diverse genes in genetic...niques may allow breeders and researchers to use t... and create new varieties that were not easily pos...of Science , the researchers, whose senior and fi...st map of haplotypes sets of closely linked gene ...
Breaking Biology News(10 mins):U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Microorganism may provide key to combating giant salvinia throughout Louisiana 2New map of variation in maize genetics holds promise for developing new varieties 2H1N1 Swine Flu Leads to Cancellation of HIV AIDS Summer Camp One Heartland Announces Campaign to Fund Alternative Camp Session for 82 Children 52777 1H1N1 Swine Flu Leads to Cancellation of HIV AIDS Summer Camp One Heartland Announces Campaign to Fund Alternative Camp Session for 82 Children 52777 2Diplomat Specialty Pharmacy Receives Regional Good Neighbor Pharmacy Of The Year Award 52775 1Diplomat Specialty Pharmacy Receives Regional Good Neighbor Pharmacy Of The Year Award 52775 2Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI 1007 for Treatment of Glaucoma 52773 1Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI 1007 for Treatment of Glaucoma 52773 2Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI 1007 for Treatment of Glaucoma 52773 3
...ous mechanism used by a particular enzyme to modif...come a step closer to designing a new kind of drug...their tracks. Their research will be published in ...have known for many years that an enzyme called Da...regulating gene expression in many bacteria. Each ...
...um that can survive encounters with specific immun... that these plentiful white blood cells, known as ...l permit or prevent bacterial infections. A paper ...in The Journal of Immunology. Frank R. DeLeo, Ph.D...he National Institute of Allergy and Infectious Di...
...embryonic stem cell research receives a tremendous...lso exploring the potential of adult stem cells fo...difficulties. Although adult stem cell research is...mbryonic stem cells, adult stem cells are extremel...ab dish. Now, as reported in the May 6 issue of th...
Other Biology News:Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3Researchers discover mechanism for multiplying adult stem cells 2
Mouse Anti-Cohesin (Scc1 / Rad21) Monoclonal Antibody, Unconjugated, Clone CM110-2C10 from MBL International
Chicken Anti-Human Proline-serine-threonine phosphatase-interacting protein 2 Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Mouse Anti-Human gamma Glutamyl Transferase (gammaGT) Monoclonal Antibody, Unconjugated from AnaSpec
...to Cholesterol Oxidase Immunogen Cholesterol Oxi...ross-reacts with bacteria. Not yet tested in other...dases exist as both type I and type II oxidases an...ition, they are important as clinical reagents, po...
Biology Products: